CY1115077T1 - Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου - Google Patents

Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου

Info

Publication number
CY1115077T1
CY1115077T1 CY20131100293T CY131100293T CY1115077T1 CY 1115077 T1 CY1115077 T1 CY 1115077T1 CY 20131100293 T CY20131100293 T CY 20131100293T CY 131100293 T CY131100293 T CY 131100293T CY 1115077 T1 CY1115077 T1 CY 1115077T1
Authority
CY
Cyprus
Prior art keywords
azadicylic
octane
union
crystal forms
crystalline
Prior art date
Application number
CY20131100293T
Other languages
Greek (el)
English (en)
Inventor
Sean Dalziel
Leticia M Preza
Miroslav Rapta
Pierre-Jean Colson
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39620376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115077(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Publication of CY1115077T1 publication Critical patent/CY1115077T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20131100293T 2007-02-28 2013-04-08 Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου CY1115077T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90409007P 2007-02-28 2007-02-28
EP08726162A EP2132204B1 (en) 2007-02-28 2008-02-27 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Publications (1)

Publication Number Publication Date
CY1115077T1 true CY1115077T1 (el) 2016-12-14

Family

ID=39620376

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100293T CY1115077T1 (el) 2007-02-28 2013-04-08 Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου

Country Status (26)

Country Link
US (7) US7943772B2 (enExample)
EP (1) EP2132204B1 (enExample)
JP (2) JP5512289B2 (enExample)
KR (1) KR101480530B1 (enExample)
CN (1) CN101616916B (enExample)
AR (2) AR065554A1 (enExample)
AU (1) AU2008219615B2 (enExample)
BR (1) BRPI0807974B8 (enExample)
CA (1) CA2678073C (enExample)
CL (1) CL2008000573A1 (enExample)
CO (1) CO6220856A2 (enExample)
CY (1) CY1115077T1 (enExample)
DK (1) DK2132204T3 (enExample)
ES (1) ES2402031T3 (enExample)
HR (1) HRP20130193T1 (enExample)
IL (1) IL200131A (enExample)
MX (1) MX2009009141A (enExample)
MY (1) MY148318A (enExample)
NZ (1) NZ578871A (enExample)
PL (1) PL2132204T3 (enExample)
PT (1) PT2132204E (enExample)
RU (1) RU2458061C2 (enExample)
SI (1) SI2132204T1 (enExample)
TW (1) TWI409067B (enExample)
WO (1) WO2008106159A1 (enExample)
ZA (1) ZA200905832B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2195313B1 (en) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
PT3277278T (pt) * 2015-04-02 2020-04-16 Theravance Biopharma R&D Ip Llc Forma farmacêutica de combinação de um antagonista do recetor opioide mu e um agente opioide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6467084B1 (en) * 1999-12-16 2002-10-15 Emware, Inc. Systems and methods for reprogramming an embedded device with program code using relocatable program code
KR20030009376A (ko) 2000-03-03 2003-01-29 오르토-맥네일 파마슈티칼, 인코퍼레이티드 3-(디아릴메틸렌)-8-아자비사이클로[3.2.1]옥탄 유도체
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GEP20084300B (en) * 2001-10-22 2008-02-11 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
JP3984281B2 (ja) * 2003-04-14 2007-10-03 ファイザー・プロダクツ・インク ３−アザビシクロ〔３，２，１〕オクタン誘導体
CA2522199A1 (en) 2003-04-15 2004-10-28 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
MX2009004965A (es) 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型

Also Published As

Publication number Publication date
IL200131A0 (en) 2010-04-15
KR20090115767A (ko) 2009-11-05
US20080207676A1 (en) 2008-08-28
JP5512289B2 (ja) 2014-06-04
WO2008106159A1 (en) 2008-09-04
US8536335B2 (en) 2013-09-17
US20160287572A1 (en) 2016-10-06
PL2132204T3 (pl) 2013-06-28
US10426766B2 (en) 2019-10-01
EP2132204A1 (en) 2009-12-16
BRPI0807974B8 (pt) 2021-05-25
US20150073014A1 (en) 2015-03-12
AU2008219615B2 (en) 2013-05-09
AR109224A2 (es) 2018-11-07
BRPI0807974A2 (pt) 2014-09-16
RU2009135834A (ru) 2011-04-10
US8247555B2 (en) 2012-08-21
DK2132204T3 (da) 2013-04-29
RU2458061C2 (ru) 2012-08-10
TW200845984A (en) 2008-12-01
HRP20130193T1 (hr) 2013-03-31
PT2132204E (pt) 2013-03-25
CN101616916A (zh) 2009-12-30
US20140080856A1 (en) 2014-03-20
TWI409067B (zh) 2013-09-21
US20110184008A1 (en) 2011-07-28
MY148318A (en) 2013-03-29
ZA200905832B (en) 2010-05-26
ES2402031T3 (es) 2013-04-26
SI2132204T1 (sl) 2013-05-31
MX2009009141A (es) 2009-09-03
AR065554A1 (es) 2009-06-17
AU2008219615A1 (en) 2008-09-04
JP2010520198A (ja) 2010-06-10
US7943772B2 (en) 2011-05-17
NZ578871A (en) 2012-01-12
CA2678073C (en) 2016-01-05
KR101480530B1 (ko) 2015-01-08
CO6220856A2 (es) 2010-11-19
IL200131A (en) 2013-03-24
CL2008000573A1 (es) 2008-05-16
JP2013151564A (ja) 2013-08-08
BRPI0807974B1 (pt) 2020-11-24
US8816091B2 (en) 2014-08-26
US20180200246A1 (en) 2018-07-19
CN101616916B (zh) 2011-10-12
US9290491B2 (en) 2016-03-22
US20130072515A1 (en) 2013-03-21
HK1139399A1 (en) 2010-09-17
US9949963B2 (en) 2018-04-24
EP2132204B1 (en) 2013-01-23
CA2678073A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
CY1115077T1 (el) Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
UY29246A1 (es) Nuevos compuestos
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
UY31672A1 (es) &#34;agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación&#34;
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CY1125224T1 (el) Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη
TW200643020A (en) Crystalline form of a quinolinone-carboxamide compound
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
BR112012026509A2 (pt) &#34;novos derivados de benzamida&#34;
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate